title: [A 45-fold liraglutide overdose did not cause hypoglycaemia].
abstract: Glucagon-like peptide (GLP)-1 analogues such as liraglutide have gained popularity in the treatment of type 2 diabetes over the last years. By mimicking the effects of the native GLP-1, it enhances the glucose-dependent secretion of insulin, suppresses elevated glucagon secretion, increases satiety and slows down gastric emptying. Because of its ways of action it is not likely to cause hypoglycaemia in cases of overdosage. We present a 45-fold overdose of liraglutide (confirmed by P-liraglutide measurements) leading to nausea and vomiting, but no hypoglycaemia and no sign of pancreatitis.
authors: Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C. leemas@rm.dk.
authors: Lene Ring
authors: LR
authors: Madsen
authors: Jens Juel
authors: JJ
authors: Christiansen
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D062787:Drug Overdose / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000506:poisoning; D006801:Humans; D007003:Hypoglycemia / Q000097:blood; D007004:Hypoglycemic Agents / Q000506:poisoning*; D000069450:Liraglutide / Q000506:poisoning*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1